Bioavailability and cytosolic kinases modulate response to deoxynucleoside therapy in TK2 deficiency.

EBioMedicine · 2019 · PMC6710986 · PMID 31383553

Europe PMC DOI

hedged sentence

0.3200

closest p · 6.4× alpha

0.3200

boldest claim

The sentences

a mild trendp = 0·32not close (p > 0.1)

4 ), although a mild trend towards longer survival was observed in mice with oral treatment (Tk2 −/− IP dCtd+dThd , 40·2 ± 13·3 vs Tk2 −/− oraldCtd+dThd , 43·2 ± 11·1; p = 0·32).

also in 257 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.